Licence extension for Apidra

The licence for Apidra (insulin glulisine) has been extended.

The new licence includes the treatment of adolescents and children aged six years and over with diabetes. Apidra was previously indicated for use in adults only.


Further information: Sanofi-aventis

 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more